Do you or does someone you know have metastatic colorectal cancer? If so, you may be eligible to participate in an important clinical research program. Novartis is conducting clinical research studies, called TRACT-1 and TRACT-2, to investigate a drug called RAD001 in patients with metastatic colorectal cancer. You may be eligible to participate if you are:   18 years of age or older.    Diagnosed with metastatic colorectal cancer,that has progressed after standard therapies treatment (ie, anti-EGFR antibodies such as Erbitux® [cetuximab]or Vectibix® [panitumumab], Avastin® [bevacizumab], fluoropyrimidine, Eloxatin® [oxaliplatin], and Camptosar® [irinotecan]). Patients who participate will be monitored closely throughout their treatment by highly trained doctors and nurses who specialize in colorectal cancer research and treatment.    If you would like to see if you qualify to participate in a Novartis research study, click on the button below.